Imx-110
Phase 1/2UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor, Adult
Conditions
Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer, Ovarian Cancer
Trial Timeline
Feb 15, 2018 → Dec 31, 2023
NCT ID
NCT03382340About Imx-110
Imx-110 is a phase 1/2 stage product being developed by Immix Biopharma for Solid Tumor, Adult. The current trial status is unknown. This product is registered under clinical trial identifier NCT03382340. Target conditions include Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03382340 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Solid Tumor, Adult